A team of scientists from the Hope Center for Neurological Disorders has completed phase one of a research project that developed an innovative way to treat ALS. Dr. Timothy Miller, director of the Christopher Wells Hobler Lab for ALS research at the Hope Center, spearheaded the researcher that identified a way to turn off harmful genes in the brain and spinal cord as a way to stop ALS.

Interviewed recently on KPLR television in St. Louis, Dr. Miller said, “We can do go in a technique called antisense oligo nucleotides and take that small mistake in those RNA instructions and like a small eraser and go in an erase that mistake and fix it.” said Dr. Timothy Miller. Washington University made history this year by conducting the first ever human trials. The first phase focused on whether the drug called antisense oligo nucleotide was safe.

Click here for the KPLR interview with Dr. Miller.